{"transactions":[{"id":740616,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance-Based Restricted Stock Unit","published_at":"2026-06-12T20:30:12.000Z","date":"2026-06-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":49243,"price":180,"value":8863740.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units (\"PSUs\") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the \"Issuer\"), Danaher Corporation (\"Parent\"), and Mobius Merger Sub, Inc. (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units (\"PSUs\") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the \"Issuer\"), Danaher Corporation (\"Parent\"), and Mobius Merger Sub, Inc. (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's performance-based restricted stock units (\"PSUs\") outstanding as of immediately prior to the effective time of the Merger, as determined at target performance, were canceled and converted into the right to receive $180.00 for each share of Common Stock underlying such award of PSUs, without interest and less any applicable tax withholding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Represents the PSUs granted on March 11, 2025, which represented the right to receive shares of Common Stock over a three year performance period, determined at target performance."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":49243},"source":{"system":"sec-edgar","filing":"0001104659-26-073506","document":"tm2617401-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/937556/000110465926073506/tm2617401-16_4seq1.xml","form_type":"4"}},{"id":740615,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2026-06-12T20:30:12.000Z","date":"2026-06-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18617,"price":13.48,"value":250957.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the \"Issuer\"), Danaher Corporation (\"Parent\"), and Mobius Merger Sub, Inc. (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the \"Issuer\"), Danaher Corporation (\"Parent\"), and Mobius Merger Sub, Inc. (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's stock options outstanding as of immediately prior to the effective time of the Merger, whether vested or unvested, were canceled and converted into the right to receive, for each share of Common Stock subject to such option, the excess, if any, of the Per Share Merger Consideration over the exercise price per share of such option, without interest and less any applicable tax withholding."}],"balance_after":0,"derivative":{"exercise_price":166.52,"underlying":"Common Stock","underlying_shares":18617},"source":{"system":"sec-edgar","filing":"0001104659-26-073506","document":"tm2617401-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/937556/000110465926073506/tm2617401-16_4seq1.xml","form_type":"4"}},{"id":740614,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-06-12T20:30:12.000Z","date":"2026-06-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":39904,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units (\"RSUs\") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the \"Issuer\"), Danaher Corporation (\"Parent\"), and Mobius Merger Sub, Inc. (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units (\"RSUs\") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the \"Issuer\"), Danaher Corporation (\"Parent\"), and Mobius Merger Sub, Inc. (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units (\"RSUs\") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Represents the unvested portion of RSUs granted on March 6, 2026, which award of RSUs was to vest ratably over four years."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":39904},"source":{"system":"sec-edgar","filing":"0001104659-26-073506","document":"tm2617401-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/937556/000110465926073506/tm2617401-16_4seq1.xml","form_type":"4"}},{"id":740613,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-06-12T20:30:12.000Z","date":"2026-06-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6306,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units (\"RSUs\") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the \"Issuer\"), Danaher Corporation (\"Parent\"), and Mobius Merger Sub, Inc. (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units (\"RSUs\") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the \"Issuer\"), Danaher Corporation (\"Parent\"), and Mobius Merger Sub, Inc. (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units (\"RSUs\") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Represents the unvested portion of RSUs granted on March 11, 2025, which award of RSUs was to vest ratably over four years."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6306},"source":{"system":"sec-edgar","filing":"0001104659-26-073506","document":"tm2617401-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/937556/000110465926073506/tm2617401-16_4seq1.xml","form_type":"4"}},{"id":740612,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-06-12T20:30:12.000Z","date":"2026-06-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22283,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units (\"RSUs\") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the \"Issuer\"), Danaher Corporation (\"Parent\"), and Mobius Merger Sub, Inc. (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units (\"RSUs\") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the \"Issuer\"), Danaher Corporation (\"Parent\"), and Mobius Merger Sub, Inc. (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On June 10, 2026, at the effective time of the Merger, each of the Issuer's restricted stock units (\"RSUs\") (other than certain RSUs held by the Issuer's non-employee directors) was assumed by Parent and converted into a number of RSUs of Parent equal to the product of the number of shares of Parent common stock equal to the number of shares of Common Stock underlying such RSU multiplied by the quotient of (a) the Per Share Merger Consideration, divided by (b) the volume-weighted average trading price per share of Parent's common stock for the ten trading day period ending on and including June 10, 2026 ($183.33)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents the unvested portion of RSUs granted on February 12, 2025, which award of RSUs was to vest ratably over three years."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22283},"source":{"system":"sec-edgar","filing":"0001104659-26-073506","document":"tm2617401-16_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/937556/000110465926073506/tm2617401-16_4seq1.xml","form_type":"4"}},{"id":740611,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-12T20:30:12.000Z","date":"2026-06-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7605,"price":180,"value":1368900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 10, 2026, pursuant to the Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo Corporation (the \"Issuer\"), Danaher Corporation (\"Parent\"), and Mobius Merger Sub, Inc. (\"Merger Sub\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 10, 2026, at the effective time of the Merger, each share of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\") issued and outstanding prior to the effective time of the Merger (other than certain excluded shares and dissenting shares) was canceled, extinguished and converted into the right to receive an amount in cash equal to $180.00 per share, without interest (the \"Per Share Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-073506","document":"tm2617401-16_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/937556/000110465926073506/tm2617401-16_4seq1.xml","form_type":"4"}},{"id":842578,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2026-03-16T21:21:00.000Z","date":"2026-03-11","kind":"exercise","planned":false,"acquired":false,"shares":2101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As previously reported, the reporting person was granted 8,407 restricted stock units (RSUs) on March 11, 2025 and will vest ratably over four years, 25% of which vested on March 11, 2026."}],"balance_after":6306,"derivative":{"expiration_date":"2035-03-11","underlying":"Common Stock","underlying_shares":2101},"source":{"system":"sec-edgar","filing":"0000937556-26-000044","document":"wk-form4_1773696057.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/937556/000093755626000044/wk-form4_1773696057.xml","form_type":"4"}},{"id":842577,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-03-16T21:21:00.000Z","date":"2026-03-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":1069,"price":175.47,"value":187577.43,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain RSUs."}],"balance_after":7605,"source":{"system":"sec-edgar","filing":"0000937556-26-000044","document":"wk-form4_1773696057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/937556/000093755626000044/wk-form4_1773696057.xml","form_type":"4"}},{"id":842576,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-03-16T21:21:00.000Z","date":"2026-03-11","kind":"exercise","planned":false,"acquired":true,"shares":2101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As previously reported, the reporting person was granted 8,407 restricted stock units (RSUs) on March 11, 2025 and will vest ratably over four years, 25% of which vested on March 11, 2026."}],"balance_after":8674,"source":{"system":"sec-edgar","filing":"0000937556-26-000044","document":"wk-form4_1773696057.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/937556/000093755626000044/wk-form4_1773696057.xml","form_type":"4"}},{"id":852009,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2026-03-10T22:50:05.000Z","date":"2026-03-06","kind":"grant","planned":false,"acquired":true,"shares":39904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This RSU award was granted on March 6, 2026 and will vest ratably over four years, with 25% of the award vesting on each anniversary of the grant date."}],"balance_after":39904,"derivative":{"expiration_date":"2036-03-06","underlying":"Common Stock","underlying_shares":39904},"source":{"system":"sec-edgar","filing":"0000937556-26-000023","document":"wk-form4_1773183003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/937556/000093755626000023/wk-form4_1773183003.xml","form_type":"4"}},{"id":905974,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2026-02-13T22:28:49.000Z","date":"2026-02-12","kind":"exercise","planned":false,"acquired":false,"shares":11141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As previously reported, the reporting person was granted 33,424 RSUs on February 12, 2025 and will vest ratably over three years.  One-third of the RSUs vested on February 12, 2026, and the remaining RSUs will vest in two equal installments on the second and third anniversaries of the grant date."}],"balance_after":22283,"derivative":{"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":11141},"source":{"system":"sec-edgar","filing":"0000937556-26-000010","document":"wk-form4_1771021726.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/937556/000093755626000010/wk-form4_1771021726.xml","form_type":"4"}},{"id":905973,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-13T22:28:49.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":4568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain performance restricted stock units."}],"balance_after":6573,"source":{"system":"sec-edgar","filing":"0000937556-26-000010","document":"wk-form4_1771021726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/937556/000093755626000010/wk-form4_1771021726.xml","form_type":"4"}},{"id":905972,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-13T22:28:49.000Z","date":"2026-02-12","kind":"exercise","planned":false,"acquired":true,"shares":11141,"price":132.96,"value":1481307.36,"ownership":{"direct":true},"balance_after":11141,"source":{"system":"sec-edgar","filing":"0000937556-26-000010","document":"wk-form4_1771021726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/937556/000093755626000010/wk-form4_1771021726.xml","form_type":"4"}},{"id":1208336,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2025-03-14T00:20:32.000Z","date":"2025-03-11","kind":"grant","planned":false,"acquired":true,"shares":8407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This RSU award was granted on March 11, 2025 and will vest ratably over four years, with 25% of the award vesting on each anniversary of the grant date."}],"balance_after":8407,"derivative":{"expiration_date":"2035-03-11","underlying":"Common Stock","underlying_shares":8407},"source":{"system":"sec-edgar","filing":"0000937556-25-000049","document":"wk-form4_1741911626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/937556/000093755625000049/wk-form4_1741911626.xml","form_type":"4"}},{"id":1208335,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2025-03-14T00:20:32.000Z","date":"2025-03-11","kind":"grant","planned":false,"acquired":true,"shares":18617,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 11, 2025 and is exercisable as the option vests. The option vests over a five year period, with 20% of the shares subject to the option vesting on each anniversary of the grant date."}],"balance_after":18617,"derivative":{"exercise_price":166.52,"expiration_date":"2035-03-11","underlying":"Common Stock","underlying_shares":18617},"source":{"system":"sec-edgar","filing":"0000937556-25-000049","document":"wk-form4_1741911626.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/937556/000093755625000049/wk-form4_1741911626.xml","form_type":"4"}},{"id":1259667,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true}}],"security":"Stock Option","published_at":"2025-02-19T20:20:54.000Z","date":"2025-02-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":49719,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":5.7263,"underlying":"Common Stock","underlying_shares":49719},"source":{"system":"sec-edgar","filing":"0001127602-25-005758","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438538/000112760225005758/form4.xml","form_type":"4"}},{"id":1259666,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-02-19T20:20:54.000Z","date":"2025-02-19","kind":"other","planned":false,"acquired":false,"shares":22429,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated January 6, 2025, by and among Stryker Corporation (\"Parent\"), Eagle 1 Merger Sub, Inc. (\"Merger Sub\"), and Inari Medical, Inc. (\"Issuer\") on February 19, 2025 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer (\"Common Stock\") was cancelled and converted into the right to receive $80.00 in cash (the \"Merger Consideration\"), without interest."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 4,126 restricted stock units (\"RSUs\"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated January 6, 2025, by and among Stryker Corporation (\"Parent\"), Eagle 1 Merger Sub, Inc. (\"Merger Sub\"), and Inari Medical, Inc. (\"Issuer\") on February 19, 2025 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer (\"Common Stock\") was cancelled and converted into the right to receive $80.00 in cash (the \"Merger Consideration\"), without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001127602-25-005758","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438538/000112760225005758/form4.xml","form_type":"4"}},{"id":1268205,"issuer":{"id":39014,"kind":"organization","name":"MASIMO CORP","symbol":"MASI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2025-02-14T22:17:46.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":33424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (RSU) represents the contingent right to receive one share of common stock of the Issuer upon vesting of the RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This RSU award was granted on February 12, 2025 and will vest ratably over three years, with one-third of the award vesting on each of the first, second, and third anniversaries of the grant date."}],"balance_after":33424,"derivative":{"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":33424},"source":{"system":"sec-edgar","filing":"0000937556-25-000018","document":"wk-form4_1739571460.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/937556/000093755625000018/wk-form4_1739571460.xml","form_type":"4"}},{"id":1418141,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-09-03T23:10:37.000Z","date":"2024-09-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":5530,"price":69.96,"value":386878.8,"ownership":{"direct":true},"balance_after":81287.4373,"source":{"system":"sec-edgar","filing":"0001225208-24-008339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824008339/doc4.xml","form_type":"4"}},{"id":1418140,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-09-03T23:10:37.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":10910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units were granted on September 3, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are 100% vested and exercisable on the grant date."}],"balance_after":86817.4373,"source":{"system":"sec-edgar","filing":"0001225208-24-008339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824008339/doc4.xml","form_type":"4"}},{"id":1458478,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-07-08T22:26:47.000Z","date":"2024-07-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":258,"price":92.32,"value":23818.56,"ownership":{"direct":true},"balance_after":75907.4373,"source":{"system":"sec-edgar","filing":"0001225208-24-007361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824007361/doc4.xml","form_type":"4"}},{"id":1496617,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-31T16:59:43.000Z","date":"2024-04-24","kind":"grant","planned":false,"acquired":true,"shares":4126,"price":42.41,"value":174983.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted on April 24, 2024 to the Reporting Person that vest in full on the earlier of (1) the day prior to the Issuer's next annual meeting of stockholders or (2) one year from the date of grant."}],"balance_after":22429,"source":{"system":"sec-edgar","filing":"0001127602-24-017134","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438538/000112760224017134/form4a.xml","form_type":"4/A","original_submission_date":"2024-04-26"}},{"id":1519597,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-05-13T21:47:09.000Z","date":"2024-05-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":827,"price":86.72,"value":71717.44,"ownership":{"direct":true},"balance_after":76165.4373,"source":{"system":"sec-edgar","filing":"0001225208-24-005985","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824005985/doc4.xml","form_type":"4"}},{"id":1522372,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-05-09T23:36:52.000Z","date":"2024-05-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":609,"price":85.09,"value":51819.81,"ownership":{"direct":true},"balance_after":76992.4373,"source":{"system":"sec-edgar","filing":"0001225208-24-005882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824005882/doc4.xml","form_type":"4"}},{"id":1522371,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-05-09T23:36:52.000Z","date":"2024-05-07","kind":"grant","planned":false,"acquired":true,"shares":32025,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments."}],"balance_after":77601.4373,"source":{"system":"sec-edgar","filing":"0001225208-24-005882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824005882/doc4.xml","form_type":"4"}},{"id":1526682,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Performance Rights","published_at":"2024-05-06T23:18:20.000Z","date":"2024-05-04","kind":"exercise","planned":false,"acquired":false,"shares":5796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4."}],"balance_after":0,"derivative":{"exercise_date":"2024-05-04","expiration_date":"2028-05-03","underlying":"Common Stock","underlying_shares":5796},"source":{"system":"sec-edgar","filing":"0001225208-24-005706","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824005706/doc4.xml","form_type":"4"}},{"id":1526681,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-05-06T23:18:20.000Z","date":"2024-05-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":3442,"price":85.25,"value":293430.5,"ownership":{"direct":true},"balance_after":45576.4373,"source":{"system":"sec-edgar","filing":"0001225208-24-005706","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824005706/doc4.xml","form_type":"4"}},{"id":1526680,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-05-06T23:18:20.000Z","date":"2024-05-04","kind":"exercise","planned":false,"acquired":true,"shares":5796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4."}],"balance_after":49018.4373,"source":{"system":"sec-edgar","filing":"0001225208-24-005706","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824005706/doc4.xml","form_type":"4"}},{"id":1526679,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-05-06T23:18:20.000Z","date":"2024-05-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":479,"price":85.06,"value":40743.74,"ownership":{"direct":true},"balance_after":43222.4373,"source":{"system":"sec-edgar","filing":"0001225208-24-005706","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824005706/doc4.xml","form_type":"4"}},{"id":1534689,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-04-26T16:59:49.000Z","date":"2024-04-24","kind":"grant","planned":false,"acquired":true,"shares":4126,"price":42.41,"value":174983.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted on April 24, 2024 to the Reporting Person that vest in full on the earlier of (1) the day prior to the Issuer's next annual meeting of stockholders or (2) one year from the date of grant."}],"balance_after":22429,"source":{"system":"sec-edgar","filing":"0001127602-24-013478","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438538/000112760224013478/form4.xml","form_type":"4"}},{"id":1623350,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-02-23T23:51:21.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":8560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on February 22, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments."}],"balance_after":43373.571,"source":{"system":"sec-edgar","filing":"0001225208-24-002856","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824002856/doc4.xml","form_type":"4"}},{"id":1641592,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2024-02-15T22:25:32.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":36.75,"exercise_date":"2018-05-11","expiration_date":"2024-05-10","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001225208-24-002191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824002191/doc4.xml","form_type":"4"}},{"id":1641591,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2024-02-15T22:25:32.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":27000,"derivative":{"exercise_price":36.75,"exercise_date":"2018-05-11","expiration_date":"2024-05-10","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001225208-24-002191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824002191/doc4.xml","form_type":"4"}},{"id":1641590,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-02-15T22:25:32.000Z","date":"2024-02-15","kind":"sale","planned":false,"acquired":false,"shares":27000,"price":85.6168,"value":2311653.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $85.44 to $85.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":34813.571,"source":{"system":"sec-edgar","filing":"0001225208-24-002191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824002191/doc4.xml","form_type":"4"}},{"id":1641589,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-02-15T22:25:32.000Z","date":"2024-02-15","kind":"exercise","planned":false,"acquired":true,"shares":27000,"price":36.75,"value":992250.0,"ownership":{"direct":true},"balance_after":61813.571,"source":{"system":"sec-edgar","filing":"0001225208-24-002191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824002191/doc4.xml","form_type":"4"}},{"id":1641588,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-02-15T22:25:32.000Z","date":"2024-02-13","kind":"sale","planned":false,"acquired":false,"shares":20000,"price":86.46,"value":1729200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $86.00 to $86.81. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":34813.571,"source":{"system":"sec-edgar","filing":"0001225208-24-002191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824002191/doc4.xml","form_type":"4"}},{"id":1641587,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2024-02-15T22:25:32.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":36.75,"value":735000.0,"ownership":{"direct":true},"balance_after":54813.571,"source":{"system":"sec-edgar","filing":"0001225208-24-002191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520824002191/doc4.xml","form_type":"4"}},{"id":1762912,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2023-10-10T22:23:40.000Z","date":"2023-10-10","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47000,"derivative":{"exercise_price":36.75,"exercise_date":"2018-05-11","expiration_date":"2024-05-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001225208-23-009461","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823009461/doc4.xml","form_type":"4"}},{"id":1762911,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-10-10T22:23:40.000Z","date":"2023-10-10","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":72.68,"value":363400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023."}],"balance_after":34813.571,"source":{"system":"sec-edgar","filing":"0001225208-23-009461","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823009461/doc4.xml","form_type":"4"}},{"id":1762910,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-10-10T22:23:40.000Z","date":"2023-10-10","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":36.75,"value":183750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023."}],"balance_after":39813.571,"source":{"system":"sec-edgar","filing":"0001225208-23-009461","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823009461/doc4.xml","form_type":"4"}},{"id":1785081,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2023-09-08T21:29:18.000Z","date":"2023-09-08","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":52000,"derivative":{"exercise_price":36.75,"exercise_date":"2018-05-11","expiration_date":"2024-05-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001225208-23-008819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823008819/doc4.xml","form_type":"4"}},{"id":1785080,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-09-08T21:29:18.000Z","date":"2023-09-08","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":76,"value":380000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023."}],"balance_after":34813.571,"source":{"system":"sec-edgar","filing":"0001225208-23-008819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823008819/doc4.xml","form_type":"4"}},{"id":1785079,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-09-08T21:29:18.000Z","date":"2023-09-08","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":36.75,"value":183750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023."}],"balance_after":39813.571,"source":{"system":"sec-edgar","filing":"0001225208-23-008819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823008819/doc4.xml","form_type":"4"}},{"id":1812359,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2023-08-09T21:44:07.000Z","date":"2023-08-09","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":57000,"derivative":{"exercise_price":36.75,"exercise_date":"2018-05-11","expiration_date":"2024-05-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001225208-23-008138","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823008138/doc4.xml","form_type":"4"}},{"id":1812358,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-08-09T21:44:07.000Z","date":"2023-08-09","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":78.637,"value":393185.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $78.44 to $78.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":34813.571,"source":{"system":"sec-edgar","filing":"0001225208-23-008138","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823008138/doc4.xml","form_type":"4"}},{"id":1812357,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-08-09T21:44:07.000Z","date":"2023-08-09","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":36.75,"value":183750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023."}],"balance_after":39813.571,"source":{"system":"sec-edgar","filing":"0001225208-23-008138","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823008138/doc4.xml","form_type":"4"}},{"id":1832401,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2023-07-10T21:09:43.000Z","date":"2023-07-10","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":62000,"derivative":{"exercise_price":36.75,"exercise_date":"2018-05-11","expiration_date":"2024-05-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001225208-23-007434","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823007434/doc4.xml","form_type":"4"}},{"id":1832400,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-07-10T21:09:43.000Z","date":"2023-07-10","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":90.52,"value":452600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023."}],"balance_after":34813.571,"source":{"system":"sec-edgar","filing":"0001225208-23-007434","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823007434/doc4.xml","form_type":"4"}},{"id":1832399,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-07-10T21:09:43.000Z","date":"2023-07-10","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":36.75,"value":183750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023."}],"balance_after":39813.571,"source":{"system":"sec-edgar","filing":"0001225208-23-007434","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823007434/doc4.xml","form_type":"4"}},{"id":1832398,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-07-10T21:09:43.000Z","date":"2023-07-07","kind":"tax_withholding","planned":true,"acquired":false,"shares":252,"price":90.46,"value":22795.92,"ownership":{"direct":true},"balance_after":34813.571,"source":{"system":"sec-edgar","filing":"0001225208-23-007434","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823007434/doc4.xml","form_type":"4"}},{"id":1857695,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2023-06-14T00:59:53.000Z","date":"2023-06-13","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":67000,"derivative":{"exercise_price":36.75,"exercise_date":"2018-05-11","expiration_date":"2024-05-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001225208-23-006806","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823006806/doc4.xml","form_type":"4"}},{"id":1857694,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-06-14T00:59:53.000Z","date":"2023-06-13","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":85.809,"value":429045.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $85.75 to $86.23 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":35055.7795,"source":{"system":"sec-edgar","filing":"0001225208-23-006806","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823006806/doc4.xml","form_type":"4"}},{"id":1857693,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-06-14T00:59:53.000Z","date":"2023-06-13","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":36.75,"value":183750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023."}],"balance_after":40055.7795,"source":{"system":"sec-edgar","filing":"0001225208-23-006806","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823006806/doc4.xml","form_type":"4"}},{"id":1873302,"issuer":{"id":7026,"kind":"organization","name":"Outset Medical, Inc.","symbol":"OM"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-31T23:10:24.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":7681,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders"}],"balance_after":24596,"source":{"system":"sec-edgar","filing":"0001484612-23-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484612/000148461223000048/edgardoc.xml","form_type":"4"}},{"id":1884453,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-19T18:11:48.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":2412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents RSUs granted on May 18, 2023, to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2024 annual meeting."}],"balance_after":18303,"source":{"system":"sec-edgar","filing":"0001127602-23-016358","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438538/000112760223016358/form4.xml","form_type":"4"}},{"id":1894030,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Performance Rights","published_at":"2023-05-15T22:25:48.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":8175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards."}],"balance_after":8175,"derivative":{"exercise_date":"2026-05-11","underlying":"Common Stock","underlying_shares":8175},"source":{"system":"sec-edgar","filing":"0001225208-23-005915","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005915/doc4.xml","form_type":"4"}},{"id":1894029,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2023-05-15T22:25:48.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":50400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments."}],"balance_after":50400,"derivative":{"exercise_price":88.78,"exercise_date":"2024-05-11","expiration_date":"2023-05-10","underlying":"Common Stock","underlying_shares":50400},"source":{"system":"sec-edgar","filing":"0001225208-23-005915","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005915/doc4.xml","form_type":"4"}},{"id":1894028,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-05-15T22:25:48.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":6525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments."}],"balance_after":35055.7795,"source":{"system":"sec-edgar","filing":"0001225208-23-005915","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005915/doc4.xml","form_type":"4"}},{"id":1899906,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2023-05-09T23:48:36.000Z","date":"2023-05-09","kind":"exercise","planned":true,"acquired":false,"shares":75600,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":35.1967,"exercise_date":"2017-05-12","expiration_date":"2023-05-11","underlying":"Common Stock","underlying_shares":75600},"source":{"system":"sec-edgar","filing":"0001225208-23-005616","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005616/doc4.xml","form_type":"4"}},{"id":1899905,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Performance Rights","published_at":"2023-05-09T23:48:36.000Z","date":"2023-05-07","kind":"exercise","planned":true,"acquired":false,"shares":4708,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4."}],"balance_after":1292,"derivative":{"exercise_date":"2023-05-07","expiration_date":"2027-05-06","underlying":"Common Stock","underlying_shares":4708},"source":{"system":"sec-edgar","filing":"0001225208-23-005616","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005616/doc4.xml","form_type":"4"}},{"id":1899904,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-05-09T23:48:36.000Z","date":"2023-05-09","kind":"sale","planned":true,"acquired":false,"shares":75600,"price":88.9449,"value":6724234.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $88.35 to $89.14 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":28530.7795,"source":{"system":"sec-edgar","filing":"0001225208-23-005616","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005616/doc4.xml","form_type":"4"}},{"id":1899903,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-05-09T23:48:36.000Z","date":"2023-05-09","kind":"exercise","planned":true,"acquired":true,"shares":75600,"price":35.1967,"value":2660870.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 6, 2023."}],"balance_after":104130.7795,"source":{"system":"sec-edgar","filing":"0001225208-23-005616","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005616/doc4.xml","form_type":"4"}},{"id":1899902,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-05-09T23:48:36.000Z","date":"2023-05-08","kind":"tax_withholding","planned":true,"acquired":false,"shares":1376,"price":88.74,"value":122106.24,"ownership":{"direct":true},"balance_after":28530.7795,"source":{"system":"sec-edgar","filing":"0001225208-23-005616","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005616/doc4.xml","form_type":"4"}},{"id":1899901,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-05-09T23:48:36.000Z","date":"2023-05-07","kind":"tax_withholding","planned":true,"acquired":false,"shares":2154,"price":88.74,"value":191145.96,"ownership":{"direct":true},"balance_after":29906.7795,"source":{"system":"sec-edgar","filing":"0001225208-23-005616","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005616/doc4.xml","form_type":"4"}},{"id":1899900,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-05-09T23:48:36.000Z","date":"2023-05-07","kind":"exercise","planned":true,"acquired":true,"shares":4708,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4."}],"balance_after":32060.7795,"source":{"system":"sec-edgar","filing":"0001225208-23-005616","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005616/doc4.xml","form_type":"4"}},{"id":1904797,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-05-05T01:49:46.000Z","date":"2023-05-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":344,"price":88.1,"value":30306.4,"ownership":{"direct":true},"balance_after":27352.7795,"source":{"system":"sec-edgar","filing":"0001225208-23-005434","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005434/doc4.xml","form_type":"4"}},{"id":1904796,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-05-05T01:49:46.000Z","date":"2023-05-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":327,"price":87.81,"value":28713.87,"ownership":{"direct":true},"balance_after":27696.7795,"source":{"system":"sec-edgar","filing":"0001225208-23-005434","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823005434/doc4.xml","form_type":"4"}},{"id":2020696,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2023-02-13T23:33:36.000Z","date":"2022-12-06","kind":"gift","acquired":false,"shares":7676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Bona fide gift."}],"balance_after":27698.498,"source":{"system":"sec-edgar","filing":"0001225208-23-001812","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520823001812/doc5.xml","form_type":"5"}},{"id":2086386,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-12-14T16:27:58.000Z","date":"2022-12-12","kind":"gift","acquired":false,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15891,"source":{"system":"sec-edgar","filing":"0001127602-22-027454","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438538/000112760222027454/form4.xml","form_type":"4"}},{"id":2210996,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-07-08T00:14:17.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":2032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on July 7, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments."}],"balance_after":35374.498,"source":{"system":"sec-edgar","filing":"0001225208-22-008720","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822008720/doc4.xml","form_type":"4"}},{"id":2249456,"issuer":{"id":7026,"kind":"organization","name":"Outset Medical, Inc.","symbol":"OM"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-01T20:25:44.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":6880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders"}],"balance_after":16915,"source":{"system":"sec-edgar","filing":"0001484612-22-000048","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1484612/000148461222000048/edgardoc.xml","form_type":"4"}},{"id":2253275,"issuer":{"id":83035,"kind":"organization","name":"Inari Medical, Inc.","symbol":"NARI"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-27T16:28:28.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":2420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents RSUs granted on May 26, 2022, to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2023 annual meeting."}],"balance_after":31891,"source":{"system":"sec-edgar","filing":"0001127602-22-015862","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438538/000112760222015862/form4.xml","form_type":"4"}},{"id":2268869,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-05-18T01:16:37.000Z","date":"2022-05-17","kind":"tax_withholding","acquired":false,"shares":1730,"price":95.93,"value":165958.9,"ownership":{"direct":true},"balance_after":33303.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-007138","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822007138/doc4.xml","form_type":"4"}},{"id":2276577,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Performance Rights","published_at":"2022-05-11T00:53:16.000Z","date":"2022-05-08","kind":"exercise","acquired":false,"shares":12206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4."}],"balance_after":0,"derivative":{"exercise_date":"2022-05-08","expiration_date":"2026-05-07","underlying":"Common Stock","underlying_shares":12206},"source":{"system":"sec-edgar","filing":"0001225208-22-006811","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006811/doc4.xml","form_type":"4"}},{"id":2276576,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-05-11T00:53:16.000Z","date":"2022-05-08","kind":"tax_withholding","acquired":false,"shares":7428,"price":100.52,"value":746662.56,"ownership":{"direct":true},"balance_after":35033.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-006811","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006811/doc4.xml","form_type":"4"}},{"id":2276575,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-05-11T00:53:16.000Z","date":"2022-05-08","kind":"exercise","acquired":true,"shares":12206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4."}],"balance_after":42461.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-006811","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006811/doc4.xml","form_type":"4"}},{"id":2276574,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-05-11T00:53:16.000Z","date":"2022-05-07","kind":"tax_withholding","acquired":false,"shares":595,"price":100.52,"value":59809.4,"ownership":{"direct":true},"balance_after":30255.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-006811","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006811/doc4.xml","form_type":"4"}},{"id":2281170,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2022-05-05T21:52:47.000Z","date":"2022-05-04","kind":"exercise","acquired":false,"shares":23400,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":21.76,"exercise_date":"2016-05-14","expiration_date":"2022-05-13","underlying":"Common Stock","underlying_shares":23400},"source":{"system":"sec-edgar","filing":"0001225208-22-006584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006584/doc4.xml","form_type":"4"}},{"id":2281169,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Performance Rights","published_at":"2022-05-05T21:52:47.000Z","date":"2022-05-03","kind":"grant","acquired":true,"shares":4725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards."}],"balance_after":4725,"derivative":{"exercise_date":"2025-05-03","underlying":"Common Stock","underlying_shares":4725},"source":{"system":"sec-edgar","filing":"0001225208-22-006584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006584/doc4.xml","form_type":"4"}},{"id":2281168,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2022-05-05T21:52:47.000Z","date":"2022-05-03","kind":"grant","acquired":true,"shares":30600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments."}],"balance_after":30600,"derivative":{"exercise_price":105.93,"exercise_date":"2023-05-03","expiration_date":"2029-05-02","underlying":"Common Stock","underlying_shares":30600},"source":{"system":"sec-edgar","filing":"0001225208-22-006584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006584/doc4.xml","form_type":"4"}},{"id":2281167,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-05-05T21:52:47.000Z","date":"2022-05-04","kind":"sale","acquired":false,"shares":10449,"price":105.0984,"value":1098173.1816,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $104.77 to $105.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":30850.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-006584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006584/doc4.xml","form_type":"4"}},{"id":2281166,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-05-05T21:52:47.000Z","date":"2022-05-04","kind":"sale","acquired":false,"shares":9155,"price":104.1768,"value":953738.604,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $103.77 to $104.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":41299.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-006584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006584/doc4.xml","form_type":"4"}},{"id":2281165,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-05-05T21:52:47.000Z","date":"2022-05-04","kind":"sale","acquired":false,"shares":3796,"price":105.8788,"value":401915.9248,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $105.77 to $105.92. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":50454.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-006584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006584/doc4.xml","form_type":"4"}},{"id":2281164,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-05-05T21:52:47.000Z","date":"2022-05-04","kind":"tax_withholding","acquired":false,"shares":493,"price":105.93,"value":52223.49,"ownership":{"direct":true},"balance_after":54250.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-006584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006584/doc4.xml","form_type":"4"}},{"id":2281163,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-05-05T21:52:47.000Z","date":"2022-05-04","kind":"exercise","acquired":true,"shares":23400,"price":21.76,"value":509184.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."}],"balance_after":54743.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-006584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006584/doc4.xml","form_type":"4"}},{"id":2281162,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-05-05T21:52:47.000Z","date":"2022-05-03","kind":"grant","acquired":true,"shares":3775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments."}],"balance_after":31343.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-006584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822006584/doc4.xml","form_type":"4"}},{"id":2299590,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2022-04-11T23:03:27.000Z","date":"2022-04-11","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":23400,"derivative":{"exercise_price":21.76,"exercise_date":"2016-05-14","expiration_date":"2022-05-13","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001225208-22-005751","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822005751/doc4.xml","form_type":"4"}},{"id":2299589,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-04-11T23:03:27.000Z","date":"2022-04-11","kind":"sale","acquired":false,"shares":9821,"price":121.3688,"value":1191962.9848,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $120.8475 to $121.8300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":27568.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-005751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822005751/doc4.xml","form_type":"4"}},{"id":2299588,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-04-11T23:03:27.000Z","date":"2022-04-11","kind":"sale","acquired":false,"shares":6579,"price":123.0007,"value":809221.6053,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $122.9600 to $123.4000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":37389.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-005751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822005751/doc4.xml","form_type":"4"}},{"id":2299587,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-04-11T23:03:27.000Z","date":"2022-04-11","kind":"sale","acquired":false,"shares":3600,"price":122.1192,"value":439629.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $121.8500 to $122.7100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":43968.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-005751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822005751/doc4.xml","form_type":"4"}},{"id":2299586,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-04-11T23:03:27.000Z","date":"2022-04-11","kind":"exercise","acquired":true,"shares":20000,"price":21.76,"value":435200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."}],"balance_after":47568.6569,"source":{"system":"sec-edgar","filing":"0001225208-22-005751","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822005751/doc4.xml","form_type":"4"}},{"id":2336199,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2022-03-14T23:01:20.000Z","date":"2022-03-14","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":43400,"derivative":{"exercise_price":21.76,"exercise_date":"2016-05-14","expiration_date":"2022-05-13","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001225208-22-004663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822004663/doc4.xml","form_type":"4"}},{"id":2336198,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-03-14T23:01:20.000Z","date":"2022-03-14","kind":"sale","acquired":false,"shares":11853,"price":104.883,"value":1243178.199,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $104.58 to $105.15. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":27414.5223,"source":{"system":"sec-edgar","filing":"0001225208-22-004663","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822004663/doc4.xml","form_type":"4"}},{"id":2336197,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-03-14T23:01:20.000Z","date":"2022-03-14","kind":"sale","acquired":false,"shares":8147,"price":104.3111,"value":849822.5317,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $103.58 to $104.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":39267.5223,"source":{"system":"sec-edgar","filing":"0001225208-22-004663","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822004663/doc4.xml","form_type":"4"}},{"id":2336196,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-03-14T23:01:20.000Z","date":"2022-03-14","kind":"exercise","acquired":true,"shares":20000,"price":21.76,"value":435200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."}],"balance_after":47414.5223,"source":{"system":"sec-edgar","filing":"0001225208-22-004663","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822004663/doc4.xml","form_type":"4"}},{"id":2386283,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2022-02-19T00:41:45.000Z","date":"2022-02-18","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":63400,"derivative":{"exercise_price":21.76,"exercise_date":"2016-05-14","expiration_date":"2022-05-13","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001225208-22-002824","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822002824/doc4.xml","form_type":"4"}},{"id":2386282,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-02-19T00:41:45.000Z","date":"2022-02-18","kind":"sale","acquired":false,"shares":13100,"price":106.6163,"value":1396673.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $106.19 to $107.00 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":27414.5223,"source":{"system":"sec-edgar","filing":"0001225208-22-002824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822002824/doc4.xml","form_type":"4"}},{"id":2386281,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-02-19T00:41:45.000Z","date":"2022-02-18","kind":"sale","acquired":false,"shares":6900,"price":105.7361,"value":729579.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $105.19 to $106.16. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":40514.5223,"source":{"system":"sec-edgar","filing":"0001225208-22-002824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822002824/doc4.xml","form_type":"4"}},{"id":2386280,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Common Stock","published_at":"2022-02-19T00:41:45.000Z","date":"2022-02-18","kind":"exercise","acquired":true,"shares":20000,"price":21.76,"value":435200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021."}],"balance_after":47414.5223,"source":{"system":"sec-edgar","filing":"0001225208-22-002824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822002824/doc4.xml","form_type":"4"}},{"id":2435264,"issuer":{"id":3026,"kind":"organization","name":"Edwards Lifesciences Corp","symbol":"EW"},"owners":[{"id":39015,"kind":"person","name":"Szyman Catherine M.","position":1,"cik":"0001438538","reported_name":"Szyman Catherine M.","relationship":{"officer":true,"officer_title":"CVP, Critical Care"}}],"security":"Employee Stock Option (Right to Acquire)","published_at":"2022-01-15T00:16:37.000Z","date":"2022-01-14","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":83400,"derivative":{"exercise_price":21.76,"exercise_date":"2016-05-14","expiration_date":"2022-05-13","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001225208-22-000769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1099800/000122520822000769/doc4.xml","form_type":"4"}}],"next_cursor":"2022-01-15T00:16:37.000000Z,2435264"}